The annual congress of the European Society for Medical Oncology (ESMO) took place on 7–11 October 2016 at the Bella Center, Copenhagen, Denmark.
Boehringer Ingelheim hosted a satellite symposium entitled ‘Update in NSCLC treatment: Applying the evidence to clinical practice’. The meeting was chaired by Anders Mellemgaard, with presentations given by Vanesa Gregorc, Luis Paz-Ares and Glenn Goss. The interactive format of the meeting was aimed to facilitate discussion of the latest data in NSCLC treatment in the context of real-world patient cases.
For more details of the symposium please see below.
Of a special note, Boehringer Ingelheim presented overall survival data from phase IIb trial LUX-Lung 7 and the results from the phase III LUME-colon 1 study. In addition to those, five posters were presented during the poster display sessions. See below for further details.
The full ESMO 2016 programme can be found here.
Update in NSCLC treatment: Applying the evidence to clinical practice
Saturday 8 October, 13:00–14:30
Bella Center, Athens Auditorium, Copenhagen,
13:00 – 13:05
Welcome and faculty introductions
Chair: Anders Mellemgaard
13:05 – 13:30
First-line treatment of EGFR M+ NSCLC
13:30 – 13:45
Irreversible vs reversible ErbB Family blockade
13:45 – 14:05
Beyond first-line therapy in NSCLC: Going head-to-head in
advanced squamous cell carcinoma (SqCC)
14:05 – 14:25
Anti-angiogenic agents in NSCLC:
The right choice for the right patient after first-line therapy
14:25 – 14:30
Meeting summary and close